SCHEMBL873493

SCHEMBL873493

COc1ccc(N2CCNC(CN3CCc4ccccc4C3)C2)cc1OC1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.47
HTR7 P34969 1/20 0.42
POLB P06746 1/20 0.41
PDE4D Q08499 1/20 0.40
KMT2A Q03164 1/20 0.39
PRMT5 O14744 3/20 0.39
WDR77 Q9BQA1 3/20 0.39
THRB P10828 1/20 0.39
ACHE P22303 1/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682497 1.00 PDE4B (0.47) PDE4BHTR7POLBPDE4DKMT2A
Hydrochloric Acid SCHEMBL2140661 0.99 PDE4B (0.47) PDE4BHTR7POLBPDE4DKMT2A
Hydrochloric Acid SCHEMBL2140654 0.99 PDE4B (0.47) PDE4BHTR7POLBPDE4DKMT2A
SCHEMBL683224 0.94 PDE4B (0.43) PDE4BHTR7PDE4DALDH1A1MAPT
SCHEMBL873972 0.94 PDE4B (0.43) PDE4BHTR7PDE4DALDH1A1MAPT
Hydrochloric Acid SCHEMBL873276 0.94 PDE4B (0.43) PDE4BHTR7PDE4DALDH1A1MAPT
Hydrochloric Acid SCHEMBL873275 0.94 PDE4B (0.43) PDE4BHTR7PDE4DALDH1A1MAPT
SCHEMBL877008 0.85 PDE4B (0.44) PDE4BPDE4D
SCHEMBL682901 0.85 PDE4B (0.44) PDE4BPDE4D
SCHEMBL874586 0.82 PDE4B (0.48) PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US claimed
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087645-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D PDE4B 2/4885HTR7 1005/4885POLB 3240/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D PDE4B 2/4885HTR7 1005/4885POLB 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.